PA
CGEM icon

Profund Advisors’s Cullinan Oncology CGEM Stock Holding History

Profund Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608K Buy
33,403
+2,152
+7% +$32K 0.02% 496
2026
Q1 		$444K Buy
31,251
+7,969
+34% +$102K 0.02% 595
2025
Q4 		$241K Buy
+23,282
New +$210K 0.01% 1038
2025
Q2 		– Sell
-11,846
Closed -$89.7K – 1001
2025
Q1 		$89.7K Sell
11,846
-5,773
-33% -$55.4K ﹤0.01% 960
2024
Q4 		$215K Sell
17,619
-5,153
-23% -$74.1K 0.01% 973
2024
Q3 		$381K Buy
22,772
+3,420
+18% +$60.7K 0.01% 665
2024
Q2 		$337K Buy
19,352
+4,089
+27% +$87.1K 0.01% 657
2024
Q1 		$260K Buy
+15,263
New +$236K 0.01% 935

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Profund Advisors's CGEM Position: Q2 2026 in Review

Profund Advisors increased its Cullinan Oncology (CGEM) stake by 6.9% in Q2 2026, buying an estimated $32K and bringing the position to 33,403 shares worth $608K. The position accounts for 0.02% of the portfolio, ranked #496.

Profund Advisors first reported a position in CGEM in Q1 2024 and has held it in 8 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Profund Advisors held 33,403 shares of Cullinan Oncology worth $608K as of Q2 2026.
  • Profund Advisors bought 2,152 Cullinan Oncology shares in Q2 2026, an estimated $32K.
  • Cullinan Oncology made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #496 holding.
  • Profund Advisors first reported a position in Cullinan Oncology in Q1 2024 and has held it in 8 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.